Nearly four decades after the first effective HIV drug was introduced, the global fight against the virus has entered a new phase. The approval of lenacapavir — the world’s first capsid-targeting HIV inhibitor — marks a scientific milestone. It reflects not just a new drug, but a deeper understanding of viral biology, drug resistance, and the long arc of persistence in medical research.
From Zidovudine to Combination Therapy
The first breakthrough in HIV treatment came in 1987 with the approval of Zidovudine, a reverse transcriptase inhibitor. It targeted the viral enzyme reverse transcriptase, preventing HIV from converting its RNA into DNA — a crucial step in its life cycle.
However, HIV quickly developed resistance. The reason lay in the virus’s biology. HIV is highly error-prone when copying its genetic material, generating numerous mutations. Some of these mutations confer drug resistance. Monotherapy, therefore, proved insufficient.
This led to the development of combination antiretroviral therapy (ART), which targets multiple viral proteins — reverse transcriptase, protease, and integrase — simultaneously. By attacking the virus at different stages, combination therapy dramatically reduced viral replication and delayed resistance, transforming HIV from a fatal disease into a manageable chronic condition.
The Capsid: A Fragile but Essential Shell
4
In 1999, researchers publishing in Science described how HIV’s capsid protein folds into its distinctive cone-shaped structure. The capsid acts as a protective shell, safeguarding the virus’s RNA and enabling infection.
Subsequent studies revealed that the capsid was surprisingly fragile. Many mutations in the capsid protein rendered the virus non-infectious. Unlike other viral components that could tolerate frequent mutations, the capsid had limited evolutionary flexibility. It had to maintain structural integrity to function.
This raised a crucial scientific question: if the capsid was essential and mutation-sensitive, could it be an effective drug target?
The Long Road to Lenacapavir
4
The answer took more than two decades. Scientists, including researchers at Gilead Sciences, worked on molecules capable of binding to the capsid and destabilising it. Early candidates faced a major obstacle: poor water solubility, limiting their effectiveness as oral drugs.
In a scientific twist, that weakness became an advantage. Poor solubility allowed the drug to act as a slow-release depot when injected. On June 18, 2025, the U.S. Food and Drug Administration approved Lenacapavir as the first capsid-based HIV inhibitor.
Administered via subcutaneous injection once every six months, lenacapavir forms a reservoir under the skin, releasing the drug gradually. Clinical trials demonstrated near-complete protection against HIV infection in high-risk individuals, making it one of the most promising advances in HIV prevention to date.
Resistance: The Inevitable Challenge
Despite its promise, lenacapavir is not immune to resistance. Research published in Science Translational Medicine showed that when lenacapavir was used without other fully active drugs, certain capsid mutations emerged that reduced its effectiveness.
However, these mutations came at a cost. Laboratory experiments demonstrated that drug-resistant viruses often replicated at only 20–30% of normal levels. In escaping the drug, HIV compromised its own structural integrity.
This reinforces a central principle of HIV treatment: no single drug can reliably suppress the virus indefinitely. Combination therapy remains essential. When lenacapavir is used alongside other active antiretrovirals, viral suppression is largely maintained.
Why the Capsid Strategy Matters Beyond HIV
The success of capsid inhibition confirms that structurally essential viral components can be highly effective drug targets. Because such regions cannot mutate freely without damaging viral fitness, resistance carries a biological penalty.
This insight has broader implications:
- Encourages capsid-focused strategies in future HIV drug development.
- Strengthens the case for long-acting injectable therapies.
- Provides a template for targeting structural proteins in other viruses.
The approach could influence antiviral research for emerging pathogens where mutation-driven resistance remains a persistent challenge.
Scientific Persistence and Public Health Impact
The journey from the first antiretroviral drug in 1987 to a long-acting capsid inhibitor in 2025 underscores the incremental nature of biomedical science. Breakthroughs often arise from decades of iterative refinement rather than sudden discovery.
Lenacapavir is not a cure, nor a vaccine. But its six-month dosing schedule and high preventive efficacy may significantly improve adherence, reduce transmission, and strengthen global HIV prevention strategies — especially in high-burden regions.
What to Note for Prelims?
- Zidovudine was the first approved antiretroviral drug targeting reverse transcriptase.
- HIV capsid is a structural protein essential for viral infectivity.
- Lenacapavir is the first FDA-approved capsid inhibitor for HIV.
- Combination therapy is the standard of care in HIV treatment to prevent resistance.
What to Note for Mains?
- Discuss the evolution of antiretroviral therapy and the challenge of drug resistance in HIV.
- Examine the role of structural biology in modern drug discovery.
- Analyse the importance of long-acting injectables in improving public health outcomes.
- Evaluate how scientific persistence shapes breakthroughs in infectious disease management.